Clinical Trial: A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07416604) titled 'A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A' on Feb. 11.

Brief Summary: The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis compared with emicizumab prophylaxis in people age 12 years and older with severe or moderate congenital hemophilia A without factor VIII (FVIII) inhibitors or with hemophilia A of any severity (severe, moderate, and mild) with FVIII inhibitors.

Study Start Date: April 30

Study Type: INTERVENTIONAL

Condition: Hemophilia A

Intervention: COMBINATION_PRODUCT: NXT007

N...